0.71
+0.1099(+18.27%)
Currency In USD
| Previous Close | 0.6 |
| Open | 0.65 |
| Day High | 0.76 |
| Day Low | 0.59 |
| 52-Week High | 2.22 |
| 52-Week Low | 0.54 |
| Volume | 1.07M |
| Average Volume | 162,945 |
| Market Cap | 6.72M |
| PE | -0.88 |
| EPS | -0.81 |
| Moving Average 50 Days | 0.68 |
| Moving Average 200 Days | 0.92 |
| Change | 0.11 |
If you invested $1000 in Biofrontera Inc. (BFRI) since IPO date, it would be worth $8.07 as of July 01, 2025 at a share price of $0.712. Whereas If you bought $1000 worth of Biofrontera Inc. (BFRI) shares 3 years ago, it would be worth $19.76 as of July 01, 2025 at a share price of $0.712.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment
GlobeNewswire Inc.
Yesterday at 12:00 PM GMT
Biofrontera Inc. has signed an agreement to acquire all US assets related to Ameluz® and RhodoLED® including New Drug Application (NDA) and associated patents from Germany-based Biofrontera AG.Under their new agreement, the effective royalty rate pai
BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG
GlobeNewswire Inc.
Jun 11, 2025 7:00 PM GMT
WOBURN, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), confirms a disclosure by the Management Board of Biofronte
Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book
GlobeNewswire Inc.
Jun 03, 2025 6:30 PM GMT
Biofrontera received patent approval for the revised formulation of Ameluz® in April 2025, extending patent protection through to December 2043.The Orange Book is published by the U.S. Food and Drug Administration (FDA) and lists all approved prescri